Background: Insulin pumps with and without hybrid closed loop technology (HCL) are now mainstream in the treatment of type 1 diabetes (T1D) . These technologies are well known to improve diabetes glucose control, safety, and quality of life.
Objective: To determine if there is a difference in overall glucose control between the current FDA approved brands of pumps including those with HCL.
Methods: A retrospective chart review was performed at Children’s Hospital Orange County to assess subjects with T1D who upgraded a device during the study period of Jan. 2021 to Dec. 2021. Subjects were divided by brand of pump (Omnipod, Medtronic 670G and Tandem Control IQ) and further categorized by upgrade device type. A1c was documented at baseline and within 3 to 6 months after pump upgrade. Statistics performed with the sign test (exact method) for paired data and Wilcoxon rank sum test comparing difference in A1c at baseline and after upgrade.
Results: 125 subjects upgraded pumps in the study period. 84 subjects were included in the A1c analysis due to data availability. Subjects ranged in age from 5 to 24 years, 48% were female, and 83% used HCL. Most subjects chose to upgrade to Tandem Control IQ (73%) vs. Omnipod (16%) or Medtronic 770G (11%) . Difference in pre-A1c to post-A1c of subjects who upgraded from Medtronic 670G [ A1c 7.9% (7.2-8.7) ] to Tandem Control IQ [A1c 7.3% (6.95-7.7) ] was statistically significant (p<0.0003) . Although other groups had mild changes in A1c, they did not reach statistical significance.
Conclusions: The majority of subjects preferred Tandem Control IQ HCL technology to other FDA approved devices. Tandem Control IQ showed significant improvement in A1c compared to Medtronic 670G in clinical practice. Further research is needed to determine if changes in A1c are sustained overtime.
C. S. Reh: None. S. Thompson: Other Relationship; Insulet Corporation, Medtronic, Tandem Diabetes Care, Inc.